Publications
67
Citations
1,507
Est. group size
~2
Recurring co-author estimate
Active years
27
Publishing since 2000
Siegfried Schmidt's research focuses on how genetic variation, drugs, and aging interact to affect medication safety and effectiveness, particularly for pain management, opioid use, and chronic disease treatment in older adults. Work spans pharmacogenetics (how genes affect drug response), deprescribing of opioids and benzodiazepines, and clinical studies examining drug interactions, chronic pain, and conditions like diabetes and hypertension. Recent projects also explore medical marijuana use and its long-term effects in older populations.
Publication output has grown over the last decade, with a notable increase in output during 2024-2025 compared to earlier, more sporadic years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Clinical Outcomes Associated with Concomitant Use of CYP3A4-Inducing Anticonvulsants and Opioids in Older Nursing Home Residents—A Target Trial Emulation Study
SSRN Electronic Journal · 2026
- Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for the Study on Medical Marijuana and its Long-Term Effects (the SMILE study) Prospective Cohort (Preprint)
2025
- Are U.S. Preventive Services Task Force Recommendations Effective? An Evaluation of the 2015 Prediabetes/Diabetes Recommendation
American Journal of Preventive Medicine · 2025
- Real-Time and Long-Term Effects of Medical Marijuana on Older Adults: Protocol for a Prospective Cohort Study
JMIR Research Protocols · 2025
- Applying evidence-based cross-disciplinary concepts helps to explain the heterogeneity in pain, function, and biological measures in individuals with knee pain with/at risk of osteoarthritis
PAIN Reports · 2024
- Deprescribing Strategies for Opioids and Benzodiazepines with Emphasis on Concurrent Use: A Scoping Review
Journal of Clinical Medicine · 2023
- A randomized, cross‐over trial of metoprolol succinate formulations to evaluate <scp>PK</scp> and <scp>PD</scp> end points for therapeutic equivalence
Clinical and Translational Science · 2022
- Characterizing OPRM1 DNA methylation in prescription opioid users with chronic musculoskeletal pain
PAIN Reports · 2022
- Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
The Pharmacogenomics Journal · 2021
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Diabetes Care · 2020
- Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype‐Derived Activity Scores
CPT Pharmacometrics & Systems Pharmacology · 2020
- Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings
Genetics in Medicine · 2019
- PIH13 COST IMPLICATIONS OF DRUG-DRUG INTERACTIONS WITH HORMONAL CONTRACEPTIVES: A CONCEPTUAL FRAMEWORK BASED ON LINKED PHARMACOKINETIC-PHARMACODYNAMIC-PHARMACOECONOMIC (PK-PD-PE) MODELS
Value in Health · 2019
- Whole Body Vibration. Professional vibration training with 250 Exercises. by Siegfried Schmidt Fitness
2019
- Clinical Application of Pharmacogenetics in Pain Management
Personalized Medicine · 2018
- PLoS Medicine×5
- Genetics in Medicine×2
- Journal of the American Medical Directors Association×2
- Journal of Clinical Medicine×2
- Alzheimer s & Dementia×2
- Yu‐Jung Jenny Wei
Medicine · The Ohio State University
- Justin Kullgren
Medicine · The Ohio State University
- Jeffrey T. Boon
Medicine · The Ohio State University
- Jennifer F. Waljee
Medicine · Indiana University
- Alison R. Anderson
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile